Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus TACE vs TACE as adjuvant therapy in high recurrence risk hepatocellular carcinoma
ChiCTR2400083644Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Relapse-free survival and Overall survival. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400083644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083644.